Lumateperone

Atypical antipsychotic, 5HT2A/D2 antagonist with proposed differential pre/post-synaptic D2 activity

Lumateperone

Caplyta

Lumateperone (brand name Caplyta) is an atypical antipsychotic FDA-approved in 2019 for schizophrenia and in 2021 for bipolar depression. Its receptor profile combines very high 5HT2A antagonist affinity with moderate D2 activity that is hypothesized to be differential between pre- and post-synaptic compartments, proposed mechanism is presynaptic D2 partial agonism (reducing DA release) plus postsynaptic D2 antagonism. If this differential is real, it explains efficacy at lower D2 occupancy and the favorable metabolic/motor side effect profile observed clinically. Stahl emphasizes this mechanism story; primary evidence is still preliminary. Lumateperone also has moderate SERT inhibition (mood-relevant), explaining its bipolar depression efficacy. Among atypicals, it has notably low rates of weight gain, metabolic syndrome, prolactin elevation, akathisia, and parkinsonism in trials.

Experience

👥 No personal reports yet

⚕ No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

Most common: somnolence/sedation, dry mouth, fatigue, nausea. Low rates of: metabolic effects, weight gain, prolactin elevation, akathisia, parkinsonism, tardive dyskinesia. Class warning: increased mortality in elderly dementia-related psychosis.

+ Add an effect

Pharmacodynamics

5HT2A antagonism Ki ~0.5 nM; D2 antagonism Ki ~32 nM; D1 antagonism Ki ~52 nM; α1A antagonism Ki ~73 nM; SERT inhibition Ki ~33 nM. Minimal H1, M, α2 binding (explains low sedation, no anticholinergic burden, no weight gain).

Interactions

No interactions reported yet.

+ Add an interaction

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary

Classes

Atypical antipsychotic, 5HT2A/D2 antagonist with proposed differential pre/post-synaptic D2 activity

Common uses

Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021).

Pharmacy

Starting dose

42 mg PO once daily with food (no titration)

Preparations

42 mg capsules

US FDA Max

42 mg/d

Pharmacology

Routes

Oral

Onset

Antipsychotic effect over weeks

Duration

Daily dosing

Half-life

~18 hours (terminal)

Bioavailability

Limited but adequate; take with food

Pregnancy

Limited data; National Pregnancy Registry for Atypical Antipsychotics

Legal status

Rx

Purported mechanism

Very high affinity 5HT2A receptor antagonism (~50-fold higher affinity than for D2). Moderate D2 receptor activity proposed to be differential between presynaptic (partial agonist) and postsynaptic (antagonist), if confirmed, this would explain why lumateperone has antipsychotic efficacy at D2 occupancy lower than other antipsychotics. Moderate SERT inhibition (suggests antidepressant potential).